Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are an essential part of the pharmaceutical industry, and their demand has been increasing steadily in South Africa.
Customer preferences: Bronchodilator drugs are used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The increasing prevalence of these diseases in South Africa, coupled with the rising awareness about the importance of early diagnosis and treatment, has led to a surge in demand for bronchodilator drugs. Patients prefer bronchodilator drugs as they provide quick relief from symptoms such as shortness of breath, wheezing, and coughing.
Trends in the market: The market for bronchodilator drugs in South Africa is witnessing an increasing trend of generic drugs. The availability of generic drugs at a lower cost has led to an increase in their usage. The government's efforts to promote the use of generic drugs have also contributed to this trend. Another significant trend in the market is the increasing use of combination therapy, where two or more bronchodilator drugs are used together for better efficacy.
Local special circumstances: South Africa has a high prevalence of respiratory diseases due to factors such as pollution, smoking, and tuberculosis. The country has one of the highest rates of asthma in the world, with an estimated 3.9 million people affected. The high prevalence of these diseases has led to a significant demand for bronchodilator drugs in the country.
Underlying macroeconomic factors: The South African pharmaceutical industry is heavily regulated, and the government plays a significant role in the pricing and distribution of drugs. The government's efforts to promote the use of generic drugs have led to a decrease in the prices of bronchodilator drugs, making them more affordable for patients. The increasing demand for bronchodilator drugs has also led to a rise in the number of local manufacturers, which has contributed to the growth of the pharmaceutical industry in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
